December 19, 2018 3:49am

“Bottom” development has to be close; some internal breadth have matched their lows from October


Pre-open indications: 5 HIT and 2 MISS


Out and about: AxoGen (AXGN -$6.17 or -22.41 to $21.36) sank in response to a negative report from an investor that stands to gain a great deal if the stock tanks. The short-seller has convinced enough investors AXGN's in trouble to drive the stock 22.4% lower on Tuesday. Real or imagined, wouldn't have such a big effect on the stock if investors weren't still waiting for crucial clinical trial results. AXGN began distributing the Avance Nerve Graft in 2007, but it isn't approved by the FDA yet. To satisfy the regulator, AXGN started a registry study to compare outcomes between patients receiving standard care and AxoGen's cadaver-derived product.


Investors should be reading about today’s final “figures” – be a subscriber and be ready for tomorrow’s session! As I have stated … today’s tin could be tomorrow’s gold!

Members only. Please login.